Research blog

The global M ice model (Models, services and care products) market is expected to grow at a CAGR of 7.2% during the projected period to reach USD 1,370.54 million by 2023 from USD 968.36 million in 2018. The growth of this market is mainly attributed to the continuing modification in mice model for cancers, immune diseases, and rare diseases; increasing devouring of personalized medicine propelling the demand for humanized mice model; rising grants and investments for biological research; rising pharmaceutical R&D activities; and increasing focus of International Mouse Phenotyping Consortium (IMPC) and International Knockout Mouse Consortium (IKMC) on the development of embryonic stem cells as well as knockout and mutant mice. Browse in-depth Report on: https://www.meticulousresearch.com/product/mice-model-market/ The evolution of alternative techniques to animal testing, improvement in zebrafish model development, and growing need for improved mice models are t...

The global cancer immunotherapy market study presents historical market data in terms of values (2016 and 2017), estimated current data (2018), and forecasts for 2024-by product (monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy), application (lung cancer, breast cancer, multiple myeloma, colorectal cancer, melanoma, prostate cancer, and other cancer types), and end user (hospitals, and clinics & others). The study also evaluates industry competitors and analyzes the market at regional and country level. Cancer Immunotherapy Market    On the basis of product type, monoclonal antibodies segment commanded the largest share of the global cancer immunotherapy market in 2017. However, checkpoint inhibitors market is expected to grow at the fastest CAGR during the forecast period, owing to high success rate of PD-1 & PD-L1 drugs and increasing pipelines of biotechnology and pharmaceutical companies with combination therapies...